Follow the people · Insider
Michael Myers
Michael Myers files insider transactions with the SEC as a chief executive officer of Quoin Pharmaceuticals (QNRX). We hold 1 disclosed purchase or sale filed since 30 October 2023, 1 of them in the last 90 days.
- Files forQNRX
- Disclosed buys and sells1 in all, 1 in the last 90 days
- Last disclosure1 September 2026
Positions held
1 post we hold — a term names its own dates; a run of filings only says when they filed- Filed 26 October 2023 — 31 August 2026Chief Executive Officer · Quoin Pharmaceuticals (QNRX)15 Form 4 lines · source: SEC Form 4
Everything they disclosed
15 entries, newest first — one per disclosure report, one per Form 4 line- ▲ bought on the open market 20,490 shares of Quoin PharmaceuticalsSEC Form 41 September 2026ADSs · traded 31 August 2026 · filed 1 September 2026
- ▲ bought on the open market 10,245 shares of Quoin Pharmaceuticals (a derivative holding)SEC Form 41 September 2026Ordinary Warrants (Right to Buy) · traded 31 August 2026 · filed 1 September 2026
- was granted 318,750 shares of Quoin Pharmaceuticals (a derivative holding)SEC Form 46 February 2026Share Option (Right to Buy) · traded 4 February 2026 · filed 6 February 2026
- was granted 318,750 shares of Quoin Pharmaceuticals (a derivative holding)SEC Form 46 February 2026Share Option (Right to Buy) · traded 4 February 2026 · filed 6 February 2026
- was granted 42,857 shares of Quoin Pharmaceuticals (a derivative holding)SEC Form 413 June 2025Share Option (Right to Buy) · traded 29 May 2025 · filed 13 June 2025
- was granted 42,039 shares of Quoin Pharmaceuticals (a derivative holding)SEC Form 42 June 2025Share Option (Right to Buy) · traded 29 May 2025 · filed 2 June 2025
- ▲ bought on the open market 555,556 shares of Quoin Pharmaceuticals (a derivative holding)SEC Form 427 December 2024Series F Warrants (right to buy) · traded 23 December 2024 · filed 27 December 2024
- ▲ bought on the open market 555,556 shares of Quoin Pharmaceuticals (a derivative holding)SEC Form 427 December 2024Series G Warrants (right to buy) · traded 23 December 2024 · filed 27 December 2024
- ▲ bought on the open market 555,556 shares of Quoin PharmaceuticalsSEC Form 427 December 2024Ordinary Shares · traded 23 December 2024 · filed 27 December 2024
- was granted 536,603 shares of Quoin Pharmaceuticals (a derivative holding)SEC Form 410 December 2024Share Option (Right to Buy) · traded 9 December 2024 · filed 10 December 2024
- ▲ bought on the open market 800 shares of Quoin PharmaceuticalsSEC Form 45 September 2024Ordinary Shares · traded 3 September 2024 · filed 5 September 2024
- ▲ bought on the open market 5,322 shares of Quoin PharmaceuticalsSEC Form 45 September 2024Ordinary Shares · traded 4 September 2024 · filed 5 September 2024
- ▲ bought on the open market 8,200 shares of Quoin PharmaceuticalsSEC Form 45 September 2024Ordinary Shares · traded 4 September 2024 · filed 5 September 2024
- ▲ bought on the open market 23,572 shares of Quoin PharmaceuticalsSEC Form 45 September 2024Ordinary Shares · traded 4 September 2024 · filed 5 September 2024
- was granted 80,965 shares of Quoin Pharmaceuticals (a derivative holding)SEC Form 430 October 2023Share Option (Right to Buy) · traded 26 October 2023 · filed 30 October 2023
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.